Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib and Defactinib With or Without Temozolomide in High Grade Malignant Brain Tumours (5G-RUBY)
NCT06630260Phase 2Recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Nov 2024
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of avutometinib and defactinib in glioblastoma (GBM), astrocytoma, diffuse hemispheric glioma (DHG) and 1 more (2 arms), sponsored by The Institute of Cancer Research. Primary endpoints: Safety and tolerability of investigational agent at 12 months, Preliminary antitumour activity of the investigational agent at 12 months and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
avutometinibdefactinib
03
Conditions
glioblastoma (GBM)astrocytomadiffuse hemispheric glioma (DHG)malignant primary glioma
Beyond the preview
Go deeper on NCT06630260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630260.